Clinical trials: Advanced Nonhematological Neoplasms
Advanced Nonhematological Neoplasms
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
The purpose of this study is to evaluate the safety and tolerability, recommended phase 2 dose (RP2D), and to characterize PK of TAK-228 administered once daily or once weekly to East Asian participants with advanced…
- Trial name
- NCT03370302
- Testing
- TAK-228
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 28 people
- Sponsor
- Calithera Biosciences, Inc
Advanced Nonhematological Malignancies
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
Overview of Study Design: This is a phase 1, multicenter, open-label, multiple-dose, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of TAK-960 in patients with…
- Trial name
- NCT01179399
- Testing
- TAK-960
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer
- Trial name
- NCT01045421
- Testing
- MLN8237 (Alisertib)
- Where
- 2 sites in United States
- Volunteers
- 273 people
- Sponsor
- Millennium Pharmaceuticals, Inc.